Am. J. Respir. Crit. Care Med., Volume 162, Number 3, September 2000, 941-946

Efficacy of Pamidronate for Osteoporosis in Patients with Cystic Fibrosis following Lung Transplantation

ROBERT M. ARIS, GAYLE E. LESTER, JORDAN B. RENNER, ANDREW WINDERS, A. DENENE BLACKWOOD, ROBERT K. LARK, and DAVID A. ONTJES

Divisions of Pulmonary Medicine and Endocrinology, and the Departments of Medicine, Orthopedics, and Radiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Lung transplantation with its attendant life-long immunosuppression contributes to bone loss and its sequelae, fractures and kyphosis, in patients with lung disease, many of whom already suffer from severe osteoporosis. Patients with cystic fibrosis (CF) are one of the most severely affected groups. We conducted a controlled, randomized, nonblinded trial of pamidronate (30 mg intravenously every 3 mo) with vitamin D (800 IU/d) and calcium (1 g/d) (n = 16) compared with vitamin D and calcium alone (n = 18, the control subjects) for 2 yr in 34 patients after lung transplant to improve bone mineral density (BMD). The treatment groups were similar in age, sex, baseline T-scores, renal function, hospitalization rates, immunosuppressant levels, change in lung function, and body mass index (BMI) over the study period. The patients treated with pamidronate gained 8.8 ± 2.5% and 8.2 ± 3.8% in spine and femur BMD after 2 yr in comparison to control subjects, who gained, on average (± SD), 2.6 ± 3.2 and 0.3 ± 2.2%, respectively (p  0.015 for both). Seven and six fractures occurred in the control and pamidronate groups, respectively (p > 0.2). Measures of bone resorption were highest immediately after lung transplant and improved with both pamidronate and time. Measures of bone formation were very poor after lung transplant, but recovered in the first post-lung transplant year irrespective of therapy. We conclude that pamidronate was more effective than control in improving bone mineral density after lung transplantation in patients with CF and appears to be one of the most promising agents studied to date for posttransplant osteoporosis.

This article has been cited by other articles:

				C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern Med, February 5, 2008; 148(3): 197 - 213. [Abstract] [Full Text] [PDF]

				N. M. Maalouf and E. Shane Osteoporosis after Solid Organ Transplantation J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2456 - 2465. [Abstract] [Full Text] [PDF]

				A. M. Taveira-DaSilva, M. P. Stylianou, C. J. Hedin, O. Hathaway, and J. Moss Bone Mineral Density in Lymphangioleiomyomatosis Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 61 - 67. [Abstract] [Full Text] [PDF]

				S P Conway, B Oldroyd, A Morton, J G Truscott, and D G Peckham Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study Thorax, August 1, 2004; 59(8): 699 - 703. [Abstract] [Full Text] [PDF]

				O. Gluck and G. Colice Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases Chest, May 1, 2004; 125(5): 1859 - 1876. [Abstract] [Full Text] [PDF]

				E. Shane, V. Addesso, P. B. Namerow, D. J. McMahon, S.-H. Lo, R. B. Staron, M. Zucker, S. Pardi, S. Maybaum, and D. Mancini Alendronate versus Calcitriol for the Prevention of Bone Loss after Cardiac Transplantation N. Engl. J. Med., February 19, 2004; 350(8): 767 - 776. [Abstract] [Full Text] [PDF]

				R.M. Kotloff and V.N. Ahya Medical complications of lung transplantation Eur. Respir. J., February 1, 2004; 23(2): 334 - 342. [Abstract] [Full Text] [PDF]

				R. M. Aris, G. E. Lester, M. Caminiti, A. D. Blackwood, M. Hensler, R. K. Lark, T. M. Hecker, J. B. Renner, U. Guillen, S. A. Brown, et al. Efficacy of Alendronate in Adults with Cystic Fibrosis with Low Bone Density Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 77 - 82. [Abstract] [Full Text] [PDF]

				A.A. Ionescu and E. Schoon Osteoporosis in chronic obstructive pulmonary disease Eur. Respir. J., November 2, 2003; 22(46_suppl): 64s - 75s. [Abstract] [Full Text] [PDF]

				S. L. Elkin, S. Vedi, S. Bord, N. J. Garrahan, M. E. Hodson, and J. E. Compston Histomorphometric Analysis of Bone Biopsies from the Iliac Crest of Adults with Cystic Fibrosis Am. J. Respir. Crit. Care Med., December 1, 2002; 166(11): 1470 - 1474. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594. [Full Text] [PDF]

				C S Haworth, P L Selby, J E Adams, E B Mawer, A W Horrocks, and A K Webb Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis Thorax, April 1, 2001; 56(4): 314 - 316. [Abstract] [Full Text]

				K. Wallick, J. A. Nick, and D. M. Rodman Cystic Fibrosis Critical Care . No Longer an Oxymoron Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 310 - 312. [Full Text]